65 related articles for article (PubMed ID: 38684838)
21. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
Lee CH; Mak LY; Tang EH; Lui DT; Mak JH; Li L; Wu T; Chan WL; Yuen MF; Lam KS; Wong CKH
Hepatology; 2023 Nov; 78(5):1569-1580. PubMed ID: 37055020
[TBL] [Abstract][Full Text] [Related]
22. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison.
Cho Y; Kim BH; Park JW
Clin Mol Hepatol; 2023 Apr; 29(2):252-262. PubMed ID: 36907570
[TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose Cotransporter-2 Inhibitors and Risk of Hepatocellular Carcinoma Among Patients With Type 2 Diabetes.
Bea S; Jeong HE; Kim JH; Yu OH; Azoulay L; Shin JY
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3451-3454.e4. PubMed ID: 36773883
[No Abstract] [Full Text] [Related]
24. Non-alcoholic fatty liver disease: Definition and subtypes.
Han SK; Baik SK; Kim MY
Clin Mol Hepatol; 2023 Feb; 29(suppl):S5-S16. PubMed ID: 36577427
[TBL] [Abstract][Full Text] [Related]
25. Development and prognosis of hepatocellular carcinoma in patients with diabetes.
Nakatsuka T; Tateishi R
Clin Mol Hepatol; 2023 Jan; 29(1):51-64. PubMed ID: 35903020
[TBL] [Abstract][Full Text] [Related]
26. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications.
Arvanitakis K; Koufakis T; Kotsa K; Germanidis G
Pharmacol Res; 2022 Jul; 181():106261. PubMed ID: 35588918
[TBL] [Abstract][Full Text] [Related]
27. Diabetes medications and risk of HCC.
Plaz Torres MC; Jaffe A; Perry R; Marabotto E; Strazzabosco M; Giannini EG
Hepatology; 2022 Dec; 76(6):1880-1897. PubMed ID: 35239194
[TBL] [Abstract][Full Text] [Related]
28. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease.
Zou B; Odden MC; Nguyen MH
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):435-444.e6. PubMed ID: 35158055
[TBL] [Abstract][Full Text] [Related]
29. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Goh MJ; Sinn DH
Clin Mol Hepatol; 2022 Jul; 28(3):380-395. PubMed ID: 35021597
[TBL] [Abstract][Full Text] [Related]
30. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.
Wong C; Yaow CYL; Ng CH; Chin YH; Low YF; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2020; 11():609135. PubMed ID: 33643221
[TBL] [Abstract][Full Text] [Related]
31. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.
Dwinata M; Putera DD; Hasan I; Raharjo M
Clin Exp Hepatol; 2020 Dec; 6(4):339-346. PubMed ID: 33511282
[TBL] [Abstract][Full Text] [Related]
32. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews.
Shao SC; Kuo LT; Chien RN; Hung MJ; Lai EC
BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33268450
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.
Cotter TG; Rinella M
Gastroenterology; 2020 May; 158(7):1851-1864. PubMed ID: 32061595
[TBL] [Abstract][Full Text] [Related]
34. Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus.
Cho HJ; Hwang S; Park JI; Yang MJ; Hwang JC; Yoo BM; Lee KM; Shin SJ; Lee KJ; Kim JH; Cheong JY; Cho SW; Kim SS
Gut Liver; 2019 Apr; 13(4):440-449. PubMed ID: 30970431
[TBL] [Abstract][Full Text] [Related]
35. Inverse Association of Fibrates and Liver Cancer: A Population-Based Case-Control Study in Taiwan.
Li IH; Shih JH; Tsai CS; Chien WC; Kao HH; Pan KT; Cheng YD; Kao LT
J Clin Pharmacol; 2019 Sep; 59(9):1170-1176. PubMed ID: 30964561
[TBL] [Abstract][Full Text] [Related]
36. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.
Finck BN
Diabetes; 2018 Dec; 67(12):2485-2493. PubMed ID: 30459251
[TBL] [Abstract][Full Text] [Related]
37. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
Dharmalingam M; Yamasandhi PG
Indian J Endocrinol Metab; 2018; 22(3):421-428. PubMed ID: 30090738
[TBL] [Abstract][Full Text] [Related]
39. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
[TBL] [Abstract][Full Text] [Related]
40. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Tang H; Dai Q; Shi W; Zhai S; Song Y; Han J
Diabetologia; 2017 Oct; 60(10):1862-1872. PubMed ID: 28725912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
